Cargando…
Novel C(H)1:C(L) interfaces that enhance correct light chain pairing in heterodimeric bispecific antibodies
Targeting two unique antigens with a single bispecific antibody is an attractive approach with potential broad therapeutic applicability. However, the production of heterodimeric bispecific antibodies (bsAbs) presents a challenge, requiring the co-expression and accurate pairing of two distinct heav...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914326/ https://www.ncbi.nlm.nih.gov/pubmed/28981885 http://dx.doi.org/10.1093/protein/gzx044 |
_version_ | 1783316694905651200 |
---|---|
author | Bönisch, Maximilian Sellmann, Carolin Maresch, Daniel Halbig, Claudia Becker, Stefan Toleikis, Lars Hock, Björn Rüker, Florian |
author_facet | Bönisch, Maximilian Sellmann, Carolin Maresch, Daniel Halbig, Claudia Becker, Stefan Toleikis, Lars Hock, Björn Rüker, Florian |
author_sort | Bönisch, Maximilian |
collection | PubMed |
description | Targeting two unique antigens with a single bispecific antibody is an attractive approach with potential broad therapeutic applicability. However, the production of heterodimeric bispecific antibodies (bsAbs) presents a challenge, requiring the co-expression and accurate pairing of two distinct heavy and light chain units. Several undesirable by-products can be formed in the production process, including heavy chain homodimers and non-cognate light chain pairings. Although additional downstream purification methods exist, they are often time consuming and restrict practical large-scale production. In this study, we identify and validate novel Fab interface mutations that increase cognate light chain pairing efficiencies within heterodimeric bsAbs. Importantly, the variable domains remain unaltered as interface mutations were restricted to the C(H)1 and C(L) domains. We performed several biochemical assays to demonstrate that the novel engineered interfaces do not adversely impact bispecific antibody expression, stability, affinity and biological function. The designs reported here can easily be applied in a generic manner to use existing antibodies as building blocks for bsAbs which will help to accelerate the identification and production of next generation bispecific antibody therapeutics. |
format | Online Article Text |
id | pubmed-5914326 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-59143262018-05-04 Novel C(H)1:C(L) interfaces that enhance correct light chain pairing in heterodimeric bispecific antibodies Bönisch, Maximilian Sellmann, Carolin Maresch, Daniel Halbig, Claudia Becker, Stefan Toleikis, Lars Hock, Björn Rüker, Florian Protein Eng Des Sel Original Article Targeting two unique antigens with a single bispecific antibody is an attractive approach with potential broad therapeutic applicability. However, the production of heterodimeric bispecific antibodies (bsAbs) presents a challenge, requiring the co-expression and accurate pairing of two distinct heavy and light chain units. Several undesirable by-products can be formed in the production process, including heavy chain homodimers and non-cognate light chain pairings. Although additional downstream purification methods exist, they are often time consuming and restrict practical large-scale production. In this study, we identify and validate novel Fab interface mutations that increase cognate light chain pairing efficiencies within heterodimeric bsAbs. Importantly, the variable domains remain unaltered as interface mutations were restricted to the C(H)1 and C(L) domains. We performed several biochemical assays to demonstrate that the novel engineered interfaces do not adversely impact bispecific antibody expression, stability, affinity and biological function. The designs reported here can easily be applied in a generic manner to use existing antibodies as building blocks for bsAbs which will help to accelerate the identification and production of next generation bispecific antibody therapeutics. Oxford University Press 2017-09 2017-08-31 /pmc/articles/PMC5914326/ /pubmed/28981885 http://dx.doi.org/10.1093/protein/gzx044 Text en © The Author 2017. Published by Oxford University Press. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Bönisch, Maximilian Sellmann, Carolin Maresch, Daniel Halbig, Claudia Becker, Stefan Toleikis, Lars Hock, Björn Rüker, Florian Novel C(H)1:C(L) interfaces that enhance correct light chain pairing in heterodimeric bispecific antibodies |
title | Novel C(H)1:C(L) interfaces that enhance correct light chain pairing in heterodimeric bispecific antibodies |
title_full | Novel C(H)1:C(L) interfaces that enhance correct light chain pairing in heterodimeric bispecific antibodies |
title_fullStr | Novel C(H)1:C(L) interfaces that enhance correct light chain pairing in heterodimeric bispecific antibodies |
title_full_unstemmed | Novel C(H)1:C(L) interfaces that enhance correct light chain pairing in heterodimeric bispecific antibodies |
title_short | Novel C(H)1:C(L) interfaces that enhance correct light chain pairing in heterodimeric bispecific antibodies |
title_sort | novel c(h)1:c(l) interfaces that enhance correct light chain pairing in heterodimeric bispecific antibodies |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914326/ https://www.ncbi.nlm.nih.gov/pubmed/28981885 http://dx.doi.org/10.1093/protein/gzx044 |
work_keys_str_mv | AT bonischmaximilian novelch1clinterfacesthatenhancecorrectlightchainpairinginheterodimericbispecificantibodies AT sellmanncarolin novelch1clinterfacesthatenhancecorrectlightchainpairinginheterodimericbispecificantibodies AT mareschdaniel novelch1clinterfacesthatenhancecorrectlightchainpairinginheterodimericbispecificantibodies AT halbigclaudia novelch1clinterfacesthatenhancecorrectlightchainpairinginheterodimericbispecificantibodies AT beckerstefan novelch1clinterfacesthatenhancecorrectlightchainpairinginheterodimericbispecificantibodies AT toleikislars novelch1clinterfacesthatenhancecorrectlightchainpairinginheterodimericbispecificantibodies AT hockbjorn novelch1clinterfacesthatenhancecorrectlightchainpairinginheterodimericbispecificantibodies AT rukerflorian novelch1clinterfacesthatenhancecorrectlightchainpairinginheterodimericbispecificantibodies |